Home › Idiopathic Thrombocytopenic Purpura › NCT07083960
OM336 in Autoimmune Cytopenias
RecruitingPhase 1
An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias
Who can join
Ages 18 to 75 · All sexes
Full eligibility criteria
Key Inclusion Criteria: * Active autoimmune cytopenia * Relapsed/refractory after ≥1 prior treatment * Body weight ≥ 55 kg * Willing to comply with and study requirements and procedures Key Exclusion Criteria: * Previous treatment with a BCMA-targeted therapy * Clinically significant infection within 3 months of screening * Major surgery or splenectomy within 3 months of screening or planned during the study * Pregnant or breastfeeding
About the study
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.
What is being tested
- OM336 (drug)
Sponsor: Lakefront Biotherapeutics West LLC · Participants: 32 · Started: Aug 1, 2025
Contact the study team
- Study Sponsor · Phone: 415-429-4887
Official record on ClinicalTrials.gov — NCT07083960
Locations in the U.S.
| California | City of Hope, Duarte |
| District of Columbia | Medstar, Washington D.C. |
| Michigan | University of Michigan, Ann Arbor |
| Washington | Fred Hutchinson Cancer Center, Seattle |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.